Evofem Biosciences Inc (NASDAQ:EVFM) CFO Justin J. File sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.16, for a total value of $71,600.00. Following the transaction, the chief financial officer now owns 182,251 shares of the company’s stock, valued at approximately $1,304,917.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
EVFM stock traded down $0.50 during midday trading on Wednesday, reaching $6.64. 215,615 shares of the company’s stock traded hands, compared to its average volume of 65,969. The company has a 50-day simple moving average of $5.46 and a two-hundred day simple moving average of $5.42. Evofem Biosciences Inc has a 1-year low of $3.16 and a 1-year high of $7.50. The company has a market cap of $334.22 million, a price-to-earnings ratio of -1.16 and a beta of 0.65.
Evofem Biosciences (NASDAQ:EVFM) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.01. On average, sell-side analysts anticipate that Evofem Biosciences Inc will post -1.56 earnings per share for the current fiscal year.
EVFM has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $9.00 target price on shares of Evofem Biosciences in a research report on Wednesday, October 16th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Evofem Biosciences in a research report on Wednesday, November 27th. Zacks Investment Research raised Evofem Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, November 12th. Finally, ValuEngine cut Evofem Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Evofem Biosciences currently has a consensus rating of “Hold” and a consensus target price of $8.75.
Evofem Biosciences Company Profile
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women.
Recommended Story: What is the significance of the death cross?
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.